Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 5 for:    Saved Studies
Previous Study | Return to List | Next Study

Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Parkinson's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03550183
Recruitment Status : Enrolling by invitation
First Posted : June 8, 2018
Last Update Posted : August 5, 2020
Sponsor:
Information provided by (Responsible Party):
Shengjun An, Hebei Newtherapy BIo-Pharma technology Co., Ltd.

Brief Summary:
This study is to evaluate the safety and efficacy of Umbilical Cord Derived Mesenchymal Stem Cells transplantation in Parkinson's disease.

Condition or disease Intervention/treatment Phase
Parkinson's Disease Biological: mesenchymal stem cells Phase 1

Detailed Description:
Parkinson's disease (PD) is a neurodegenerative movement disorder,which mainly shows up in the elderly. And there is as yet no effective drug treatment. Umbilical cord derived mesenchymal stem cells (UC-MSCs) derived from mesoderm owns strong proliferation ability and multiple differentiation potential. The investigators used UC-MSCs via intravenous infusion to treat PD. With different durations of follow-up, the investigators cleared therapeutic effect, the quality of life and prognostic implications of UC-MSCs on PD through the Unified Parkinson`s Disease Rating Scale (UPDRS), revised Hoehn-Yahr(H-Y) staging, Mini-Mental State Examination (MMSE), Hamilton depression scales 24 (HAMD 24), Hamilton Anxiety Scale 14 (HAMA 14) and Clinical Global Impression (CGI). In this research, the investigators seek new therapeutic approaches for PD, and provide clinical evidences for the clinical application of UC-MSCs in the future.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Efficacy Investigation of Patients With Parkinson's Disease by Transplantation of Umbilical Cord Derived Mesenchymal Stem Cells
Actual Study Start Date : January 10, 2018
Estimated Primary Completion Date : May 10, 2021
Estimated Study Completion Date : December 30, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: mesenchymal stem cells
Selected patients with Parkinson's disease were randomly divided into a therapy group and a control group. Umbilical Cord Derived Mesenchymal Stem Cells(UC-MSCs) at a dose of 10-20 million by intravenous infusion.Patients in the therapy group treated once a week with UC-MSCs. Each course of treatment Lasted 3 weeks.
Biological: mesenchymal stem cells
Patients with PD in the therapy group were given UC-MSCs by intravenous infusion and conventional therapy. There was only conventional treatment in the control group. All patients after treatment for 1 month, 3 months, 6 months and 12 months were evaluated respectively the curative effect.




Primary Outcome Measures :
  1. Changes of the Unified Parkinson`s Disease Rating Scale (UPDRS) [ Time Frame: Post cell transplantation: 1, 3, 6, 12months ]
    The UPDRS was assessed to identify the severity of PD. It includes the four-scale structure with a reorganization of the various subscales. This four-scale structure are (Part I) nonmotor experiences of daily living (13 items), (Part II) motor experiences of daily living (13 items), (Part III) motor examination (18 items), and (Part IV) motor complications (six items). Each subscale now has 0-4 ratings, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe.


Secondary Outcome Measures :
  1. Changes of in the Hoehn and Yahr staging [ Time Frame: Post cell transplantation: 1, 3, 6, 12months ]
    Hoehn and Yahr (H-Y) staging was used to determine the stage of PD based on clinical findings and functional disability. In H-Y staging is a rating scale measured in an ordinal level.

  2. Changes of the Mini-Mental State Examination (MMSE) [ Time Frame: Post cell transplantation: 1, 3, 6, 12months ]
    The MMSE was used to measure cognition. This test consists of 2 parts: language and performance. Its total score can range from 0 to 30, with a higher score indicating better function.

  3. Changes of the Hamilton depression scales 24 (HAMD 24) [ Time Frame: Post cell transplantation: 1, 3, 6, 12months ]
    The HAMD 24 is used to assessed the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. There are 24 items in the HAMD 24.

  4. Changes of the Hamilton Anxiety Scale 14 (HAMA-14) [ Time Frame: Post cell transplantation: 1, 3, 6, 12months ]
    The HAMA-14 is used to assessed the anxiety symptoms. Its total score can range from 0 to 56. Lower score represents a better outcome.

  5. Adverse reaction [ Time Frame: Post cell transplantation: 1, 3, 6, 12months ]
    Adverse reaction including temperature changes,the change of blood pressure,allergy and so on.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age from 40 to 60 years, and no limitation of gender.
  2. Diagnosis of primary Parkinson's disease(PD) according to Movement Disorder Society (MDS)-PD criteria established in 2015.
  3. Hoehn-Yahr Stages from I to IV stage.
  4. Drugs for anti Parkinson's disease have been taken over 28 days before entering the group.
  5. MMSE score≥25
  6. No antidepressant or antipsychotic drugs were received within 2 weeks.
  7. Understanding and willingness to sign a written informed consent document.

Exclusion Criteria:

Patients with PD have to be disqualified from this study if any of the following is applicable.

  1. Patients with psychiatric history, but depression.
  2. Suicidal tendency or behavior of patients.
  3. Patients with severe cognitive impairment, chronic organ failure or malignant tumor.
  4. The value of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) was 1.5 times higher than that of the normal reference; or leucocyte count<1000/μl.
  5. Pregnancy and lactating women.
  6. The patient is taking part in other drug tests, or received other research medication within 90 days before entering the group.
  7. Patients who had quit our study could not enter it again.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03550183


Locations
Layout table for location information
China, Hebei
Hebei Newtherapy BIo-Pharma Technology Co., Ltd
Shijiazhuang, Hebei, China, 050000
Sponsors and Collaborators
Hebei Newtherapy BIo-Pharma technology Co., Ltd.
Investigators
Layout table for investigator information
Study Chair: Xiqing Chai, Doctor Hebei Chemical & Pharmaceutical College
Study Director: Ping Gu, Doctor The First Hospital of Hebei Medical University
Study Director: Hongxu Chen, Master The First Hospital of Hebei Medical University
Layout table for additonal information
Responsible Party: Shengjun An, Principal Scientist & Professor, Hebei Newtherapy BIo-Pharma technology Co., Ltd.
ClinicalTrials.gov Identifier: NCT03550183    
Other Study ID Numbers: 18967728D
First Posted: June 8, 2018    Key Record Dates
Last Update Posted: August 5, 2020
Last Verified: August 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases